Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer

Onkologie

Volumn 29, Issue 3, 2006, Pages 99-105

  Macarulla, Teresa ^a   Casado, Esther ^a   Ramos, Francisco Javier ^a   Valverde, Claudia ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

EGFR; Gastrointestinal cancer; Monoclonal antibodies; Tyrosinekinase inhibitors

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMMUNOGLOBULIN G1 ANTIBODY; IRINOTECAN; MATUZUMAB; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADENOCARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ESOPHAGUS CANCER; GASTROESOPHAGUS JUNCTION CANCER; HUMAN; META ANALYSIS; MORBIDITY; NAUSEA; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DIGESTIVE SYSTEM NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GROWTH INHIBITORS; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33644776859     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091013     Document Type: Review

References (41)

1. Saltz L, Rubin MS, Hochster HS: Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 2001;20(abstr 7):3a.
2. Saltz LB, Meropol NJ, Loehrer PJ Sr: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
3. Lenz HJ, Mayer RJ, Gold PJ: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004;23(abstr 3510):248.
4. Cunningham D, Humblet Y, Siena S: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
5. Chung KY, Shia J, Kemeny NE: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
6. Moroni M, Veronese S, Benvenuti S: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-286.
7. Rosenberg AH, Loehrer PJ, Needle MN: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002;21:abstr 536.
8. Rougier P, Raoul JL, van Laethem JL: Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 2004;23(abstr 3513):248.
9. Folprecht G, Lutz MP, Seufferlein T: Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC) - final results and pharmacokinetic data of a phase I/IIa study. Proc Am Soc Clin Oncol 2005;23(abstr 3640):281s.
10. Díaz Rubio E, Tabernero J, van Cutsem E: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Proc Am Soc Clin Oncol 2005;23(abstr 3535):254s.
11. Seufferlein T, Dittrich C, Riemann J: A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 2005;23(abstr 3644):281s.
12. Ciardiello F, Bianco R, Damiano V: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-3747.
13. Saltz LB, Lenz HJ, Höchster H: Randomized phase II trial of cetuximab/Bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 2005;23(abstr 3508):248s.
14. Malik I, Hecht JR, Patnaik A: Safety and efficacy of panitumumab in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005;23 (abstr 3520):251s.
15. Berlin J, Malik I, Picus J: Panitumumab therapy with irinotecan, 5-FU, and leucovorin (IFL) in patients with metastatic colorectal cancer (mCRC). Proc ESMO 2004;abstr 265PD:iii70.
16. Mackenzie MJ, Hirte HW, Glenwood G: A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005;23:165-170.
17. Rothenberg ML, Lafleur B, Washington MK: Changes in epidermal growth factor receptor signalling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): An Eastern Cooperative Oncology Group study. Proc Am Soc Clin Oncol 2004;22(abstr 3000):14s.
18. Oza AM, Townsley CA, Siu LL: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22 (abstr 785):196.
19. Keilholz U, Arnold D, Niederle N: Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial. Proc Am Soc Clin Oncol 2005;23(abstr 3575):264s.
20. Cho CD, Fisher GA, Halsey J: A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22(abstr 1062):265.
21. Zampino MG, Lorizzo K, Massacesi C: First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer. Proc Am Soc Clin Oncol 2005;23(abstr 3659):285s.
22. Hanauske AR, Diaz-Rubio E, Cassidy: Erlotinib HCl in combination with FOLFOX-4 in patients with advanced solid tumors. Proc Am Soc Clin Oncol ASCO 2003;22(abstr 789):197.
23. Casado E, Folprecht G, Paz-Ares L: A phase 1/2A pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2004;23(abstr 3543):255s.
24. Tejpar S, Van Cutsem E, Gamelin E: A phase 1/2A study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, Leucovorin and oxaliplatin (FOL-FOX-4) in patients with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004;23(abstr 3579):264s.
25. Giralt J, Eraso A, Armengol M: Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:1460-1465.
26. Burris HA 3rd, Moore MJ, Andersen J: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
27. Overholser JP, Prewett MC, Hooper AT: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000;89:74-82.
28. Bruns CJ, Harbison MT, Davis DW: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936-1948.
29. Xiong HQ, Rosenberg A, LoBuglio A: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-2616.
30. Bangard C, Gossmann A, Papyan A: Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. Int J Cancer 2005;114:131-138.
31. Graeven U, Vogel I, Killing B: Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD72000 plus gemcitabine (Gem) in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2004;23(abstr 3061):210.
32. Blaszkowsky LS, Kulke KH, Ryan DP: A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2005;23 (abstr 4099):332s.
33. Moore MJ, Goldstein D, Hamm J: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 2005;23(abstr 1):1s.
34. Morgan JA, Bukowski RM, Xiong H: Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2003;22(abstr 788):197.
35. Rao S, Starling S, Benson M: Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD72000 (matuzumab) in combination with ECX (epirubicin, cispatin and capeitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. Proc Am Soc Clin Oncol 2005;23(abstr 4028):314s.
36. Doi T, Koizumi W, Siena S: Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22(abstr 1036):258.
37. Van Groeningen C, Richel D, Giaccone G: Gefitinib phase II study in second-line treatment of advanced esophageal cancer. Proc Am Soc Clin Oncol 2004;22(abstr 4022):318.
38. Adelstein DJ, Rybicki LA, Carroll MA: Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. Proc Am Soc Clin Oncol 2005;23(abstr 4054):321s.
39. Ferry DR, Anderson M, Beddows K: Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. Proc Am Soc Clin Oncol 2004;23 (abstr 4021):317.
40. Tew WP, Shah M, Schwartz G: Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Proc Gastrointestinal Cancer Synposium 2005;abstr 5:85.
41. Dragovich T, McCoy S, Urba SG: SWOG 0127: Phase II trial of erlotinib in GEJ and gastric adenocarcinomas. Proc Gastrointestinal Am Soc Clin Oncol Symposium 2005;abstr 49:107.